Chimeric antigen receptor (CAR) T-cell therapy, a treatment originally developed for cancer, is now being investigated for its potential to treat autoimmune diseases. This therapy involves reprogramming a patient's immune cells to target and eliminate specific cells. Hundreds of clinical trials are currently underway, exploring CAR T-cell therapy for conditions such as multiple sclerosis, lupus, Graves' disease, and vasculitis.
The goal of CAR T-cell therapy in autoimmune diseases is to reset the immune system. By eliminating the cells that mistakenly attack the body's own tissues, the therapy aims to restore the immune system to a healthy state. This approach mirrors its success in treating various blood cancers, where it has led to long-term remission for many patients.
Jan Janisch-Hanzlik, a patient with multiple sclerosis, was the first to receive this experimental treatment at the University of Nebraska Medical Center. Her symptoms, including frequent falls, had not improved with conventional medication. She pursued the trial with the hope of finding a more effective treatment and potentially preventing future generations from experiencing similar struggles, as multiple sclerosis has a genetic component.
While promising, CAR T-cell therapy for autoimmune diseases carries inherent risks and uncertainties. Researchers are still evaluating its long-term effectiveness and the duration of its benefits. Potential side effects, including dangerous inflammation, require careful monitoring. The first CAR T cancer treatment received Food and Drug Administration (FDA) approval in 2017 for an aggressive form of leukemia.
The therapy works by activating T cells, which are key immune cells. Normally, T cells identify and destroy cells infected by viruses or bacteria, or abnormal cells. In CAR T therapy, scientists engineer a patient's own T cells to specifically target and eliminate malignant cells or, in the case of autoimmune diseases, the self-attacking immune cells.
Related stories
Study Maps How Large AI Companies Influence Policy and Regulation
A new study reveals that large AI companies use tactics similar to those of Big Tobacco, Pharma, and Oil to influence AI policy and regulation.
New LED Technology Powers Insulating Nanoparticles for Infrared Light
Scientists developed a new LED technology that powers insulating nanoparticles with organic molecular antennas, producing ultra-pure near-infrared light for medical imaging and communication.
Falling Space Debris Poses Growing Risk as Spacecraft Materials Improve
Falling space debris is an increasing risk as stronger, more heat-resistant spacecraft materials prevent complete atmospheric burn-up, leading to more objects reaching Earth's surface.